Virginiamycin S1
Cat. No.：YN251681
| 产品名称: | Virginiamycin S1 |
| CAS No.: | 23152-29-6 |
| Chemical Name: | N-((6R,9S,10R,13S,15aS,22S,24aS)-22-benzyl-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1]oxa[4,7,10,13,16]pentaazacyclononadecin-9-yl)-3-hydroxypicolinamide |
| Synonyms: | |
| 分子量: | 823.89 |
| 分子式: | C₄₃H₄₉N₇O₁₀ |
| SMILES: | O=C1N2[C@](CC(CC2)=O)([H])C(N[C@@H](C3=CC=CC=C3)C(O[C@@H]([C@H](NC(C4=C(C=CC=N4)O)=O)C(N[C@H](CC)C(N5[C@](CCC5)([H])C(N(C)[C@H]1CC6=CC=CC=C6)=O)=O)=O)C)=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Virginiamycin S1 是环状十六肽抗生素，由弗氏链霉菌 (Streptomyces virginiae) 产生, 在氨酰基-tRNA 结合和肽键形成的水平上抑制细菌蛋白质合成，对多种革兰氏阳性菌显示出强大的杀菌活性。Virginiamycin S1 属于链阳性菌属家族中的 B 型化合物，与链阳性菌属家族中的 A 型化合物Virginiamycin M1 协同用于多药耐药性细菌感染。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Ningsih, F., Kitani, S., Fukushima, E., et al.VisG is essential for biosynthesis of virginiamycin S, a streptogramin type B antibiotic, as a provider of the nonproteinogenic amino acid phenylglycineMicrobiology157(Pt. 11),3213-3220(2011)
Fair, R.J., and Tor, Y.Antibiotics and bacterial resistance in the 21st centuryPerspect. Medicin. Chem.6,25-64(2014)
Kehrenberg, C., Cuny, C., Strommenger, B., et al.Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfrAntimicrob. Agents Chemother.53(2),779-781(2009)
Parfait, R., and Cocito, C.Lasting damage to bacterial ribosomes by reversibly bound virginiamycin MProc. Natl. Acad. Sci. USA77(9),5492-5496(1980)
